基于CT的影像组学评分:晚期胃癌患者的风险分层工具
这项回顾性多中心研究纳入283例晚期胃癌(cT4a/bNxM0-1)患者,构建基于原发灶和主要转移灶的CT影像组学评分(RS)预测无进展生存期(PFS)。RS在各队列中均显示出良好的预后分层能力(C-index 0.75-0.83),低评分患者更可能接受手术,仅高评分腹膜转移患者从NIPS治疗中获益。
要点
- RS可有效分层晚期胃癌患者的PFS和OS,外部验证C-index为0.76。
- 低RS患者更可能在新辅助化疗后接受手术。
- 仅高RS的腹膜转移患者从NIPS治疗中获益。
核心结论
- 基于CT的影像组学评分是晚期胃癌患者有效的风险分层工具,可用于筛选可能从NIPS治疗中获益的患者。
研究设计与样本
- 回顾性多中心研究,纳入3个中心的283例晚期胃癌患者(cT4a/bNxM0-1)。
- 一个中心患者随机分为训练组(n=166)和内部验证组(n=83),外部验证组(n=34)来自另外两个中心。
- 基于原发肿瘤和主要转移灶(腹膜、肝、淋巴结)提取影像组学特征,在训练组整合构建RS,并在验证组验证其分层PFS和OS的能力。
- 探索RS与新辅助腹腔和全身(NIPS)治疗疗效的关联。
诊断标准与关键数值
- RS预测PFS的C-index:训练组0.83(95%CI 0.788-0.872),内部验证组0.75(95%CI 0.682-0.818),外部验证组0.76(95%CI 0.669-0.851),均p<0.05。
- RS在全人群和转移亚组中均能分层PFS和OS(p<0.05)。
临床应用与阅片要点
- 可利用RS对晚期胃癌患者进行风险分层,低评分者更可能从围手术期化疗后手术中获益。
- 对于腹膜转移患者,RS高评分提示可能从NIPS治疗中获益。
局限性
- 回顾性研究设计。
- 外部验证样本量较小(n=34)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To prolong the survival, the value of a computed tomography-based radiomic score (RS) in stratifying survival and guiding personalized chemotherapy strategies in far-advanced gastric cancer (FGC) was investigated.
MATERIALS AND METHODS: This retrospective multicenter study enrolled 283 FGC patients (cT4a/bNxM0-1) from three centers. Patients from one center were randomly divided into the training (n = 166) and internal validation (n = 83) cohorts, whereas the external validation cohort (n = 34) consisted of patients from the two other centers. The RS was calculated for each patient to predict progression-free survival (PFS). Features from the primary tumor and main metastasis (peritoneum, liver, and lymph node) were integrated in the training cohort and then validated for its ability to stratify PFS and overall survival (OS) in the validation cohort. The association between the RS and efficacy of neoadjuvant intraperitoneal and systemic (NIPS) therapy was also explored.
RESULTS: The RS demonstrated a favorable prognostic ability to predict PFS in all cohorts (training: C-index 0.83, 95% confidence interval [CI]: 0.788-0.872; internal validation: C-index 0.75, 95% CI: 0.682-0.818; external validation: C-index 0.76, 95% CI: 0.669-0.851; all p < 0.05), as well as an excellent ability to stratify the PFS and OS in both the whole population and metastatic subgroups (p < 0.05). Patients with a low score were more likely to undergo surgery after perioperative chemotherapy (p < 0.05). Furthermore, only high-scoring patients with peritoneal metastasis benefited from NIPS.
CONCLUSION: The RS may be an effective risk stratifier for the outcomes of FGC patients and may be used to select patients who can benefit from NIPS therapy.
引用
- Wang, Zhu, Yan, et al. CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients. Acad Radiol. 2023. PMID: 36610930. doi:10.1016/j.acra.2022.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。